Inhibition of hypoxia-induced gene transcription by substituted pyrazolyl oxadiazoles: initial lead generation and...

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Hypoxia-inducible factors (HIF-1 and HIF-2) are key regulators of tumor cell survival, invasion, and metastasis under low oxygen conditions.
• HIFs also contribute to resistance against apoptosis, making them attractive therapeutic targets in cancer research.

Purpose of the Study:

• To identify and optimize novel small molecules that inhibit the transactivation activity of HIF-1 and HIF-2.
• To develop potent HIF inhibitors with improved metabolic stability and favorable pharmacokinetic profiles for potential cancer treatment.

Main Methods:

• A cell-based screening approach was employed to discover initial hit compounds.
• Chemical optimization of lead compounds, focusing on substituted 1H-pyrazole-3-carboxamides, was performed.
• Potency was assessed by measuring the inhibition of hypoxia-induced HIF-1α and HIF-2α accumulation (IC₅₀ values).
• Inhibition of HIF target gene expression was evaluated in A549 human lung adenocarcinoma cells.
• Pharmacokinetic studies were conducted in rats following intravenous (i.v.) and oral (p.o.) administration.

Main Results:

• A cell-based screen identified substituted 1H-pyrazole-3-carboxamides as inhibitors of HIF.
• Chemical optimization led to novel 5-(1H-pyrazol-3-yl)-1,2,4-oxadiazoles with significantly improved HIF inhibitory potency (IC₅₀ from 190 nM to 0.7 nM).
• A key compound demonstrated suppression of hypoxia-induced HIF target gene expression in A549 cells and exhibited favorable pharmacokinetics in rats.

Conclusions:

• Novel 5-(1H-pyrazol-3-yl)-1,2,4-oxadiazoles effectively inhibit HIF-1 and HIF-2 accumulation and activity.
• These compounds represent promising drug candidates for cancer therapy targeting the HIF pathway.
• The optimized compounds possess potent activity, good metabolic stability, and favorable pharmacokinetic properties.